Moleculin Biotech (NASDAQ:MBRX) vs. Acumen Pharmaceuticals (NASDAQ:ABOS) Head to Head Review

Moleculin Biotech (NASDAQ:MBRX) and Acumen Pharmaceuticals (NASDAQ:ABOS) are both small-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their institutional ownership, dividends, profitability, analyst recommendations, valuation, earnings and risk.

Risk and Volatility

Moleculin Biotech has a beta of 1.77, indicating that its stock price is 77% more volatile than the S&P 500. Comparatively, Acumen Pharmaceuticals has a beta of 0.34, indicating that its stock price is 66% less volatile than the S&P 500.

Valuation and Earnings

This table compares Moleculin Biotech and Acumen Pharmaceuticals”s gross revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Moleculin Biotech	N/A	N/A	-$33.56 million	($17.98)	-0.14
Acumen Pharmaceuticals	N/A	N/A	-$121.33 million	($1.86)	-1.23

Acumen Pharmaceuticals is trading at a lower price-to-earnings ratio than Moleculin Biotech, indicating that it is currently the more affordable of the two stocks.

Institutional and Insider Ownership

15.5% of Moleculin Biotech shares are owned by institutional investors. Comparatively, 71.0% of Acumen Pharmaceuticals shares are owned by institutional investors. 1.1% of Moleculin Biotech shares are owned by company insiders. Comparatively, 10.2% of Acumen Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Analyst Recommendations

This is a breakdown of current recommendations for Moleculin Biotech and Acumen Pharmaceuticals, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Moleculin Biotech	1	0	2	0	2.33
Acumen Pharmaceuticals	1	0	3	0	2.50

Moleculin Biotech presently has a consensus target price of $22.00, indicating a potential upside of 776.49%. Acumen Pharmaceuticals has a consensus target price of $6.67, indicating a potential upside of 191.12%. Given Moleculin Biotech’s higher probable upside, research analysts plainly believe Moleculin Biotech is more favorable than Acumen Pharmaceuticals.

Profitability

This table compares Moleculin Biotech and Acumen Pharmaceuticals’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Moleculin Biotech	N/A	N/A	-70.93%
Acumen Pharmaceuticals	N/A	-123.07%	-79.41%

Summary

Moleculin Biotech beats Acumen Pharmaceuticals on 6 of the 11 factors compared between the two stocks.

About Moleculin Biotech

Moleculin Biotech, Inc., a clinical stage pharmaceutical company, focuses on the development of drug candidates for the treatment of cancers and viruses. Its lead drug candidate is Annamycin, which is in Phase 1B/2 clinical trials for the treatment of relapsed or refractory acute myeloid leukemia (AML) and soft tissue sarcoma metastasized to the lungs. The company is also developing WP1066, an immune/transcription modulator designed to inhibit phosphorylated signal transducer and activator of transcription and other oncogenic transcription factors targeting brain tumors, and pancreatic and other cancers. In addition, it develops WP1220, an analog of WP1066 for the topical treatment of cutaneous T-cell lymphoma; and WP1122 to treat viruses, as well as cancer indications, including brain tumors, and pancreatic and other cancers. The company was incorporated in 2015 and is headquartered in Houston, Texas.

About Acumen Pharmaceuticals

Acumen Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops targeted therapies for the treatment of Alzheimer’s disease. The company focuses on advancing a targeted immunotherapy drug candidate sabirnetug (ACU193), a recombinant humanized immunoglobulin gamma 2 that completed Phase I clinical trial to target soluble amyloid-beta oligomers. The company has a license agreement with Lonza Sales AG to manufacture and commercialize sabirnetug; and a collaboration and license agreement with Halozyme, Inc. for the development of a subcutaneous formulation of sabirnetug. Acumen Pharmaceuticals, Inc. was incorporated in 1996 and is headquartered in Charlottesville, Virginia.